| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.06. | THERANEXUS: Theranexus and BBDF confirm positive 18-month results for Batten-1 in Phase I/II trial based on neurofilaments, a biomarker of neuronal death | 251 | Actusnews Wire | Lyon, France - Austin, Texas, United States - June 6, 2024 - 7:30 am CET - Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases, and the Beyond Batten... ► Artikel lesen | |
| 29.04. | THERANEXUS PUBLISHES ITS 2023 FULL-YEAR RESULTS AND PRESENTS ITS PROGRESS REPORT | 434 | Actusnews Wire | Lyon, France - 29 April 2024 - 6pm CET - Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases, today publishes its results for the year ending 31 December... ► Artikel lesen | |
| 23.04. | THERANEXUS: Theranexus, Diverchim and Inserm awarded EUR 4.7 million in funding under the "Innovations in biotherapies and biomanufacturing" call for proposals from France 2030 to develop a novel antisense oligonucleotide | 252 | Actusnews Wire | Lyon, April 23rd, 2024
Sponsors of the PickASO project, a winner of the "Innovations in biotherapies and biomanufacturing" call for proposals from France 2030, Theranexus, Diverchim and Inserm's... ► Artikel lesen | |
| 18.04. | THERANEXUS: Theranexus and BBDF announce final and positive safety and efficacy data in the Phase I/II trial testing Batten-1 | 302 | Actusnews Wire | Stabilization of motor symptom progression in young adult patients suffering from juvenile Batten disease (CLN3) after 18 months of treatment
Lyon, France - Austin, Texas, United States - 18 April... ► Artikel lesen | |
| 11.03. | THERANEXUS ANNOUNCES APPOINTMENT OF MATHIEU CHARVÉRIAT AS BOARD OF DIRECTORS CHAIRMAN | 250 | Actusnews Wire | Lyon, France - 11 March - 8:00 am CET - Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases, today announces the appointment of Mathieu Charvériat... ► Artikel lesen | |
| 14.02. | THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2023 AND PRESENTS AN UPDATE ON ITS PROGRAMS | 311 | Actusnews Wire | Lyon, France - 14 February - 6pm CEST - Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases, today announces publication of its cash position as at... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| NVIDIA | 432 |
| SNOWFLAKE | 300 |
| TUI | 267 |
| GAMESTOP | 260 |
| RHEINMETALL | 230 |
| EVOTEC | 186 |
| DEUTSCHE LUFTHANSA | 174 |
| NEL | 169 |
| BAYER | 157 |
| BYD | 140 |
| TESLA | 136 |
| VOLKSWAGEN | 106 |
| APPLE | 101 |
| BASF | 98 |
| PORSCHE SE | 92 |
| DEUTSCHE TELEKOM | 88 |
| THYSSENKRUPP | 87 |
| MERCEDES-BENZ | 83 |
| ALLIANZ | 78 |
| DEUTSCHE BANK | 78 |
| COMMERZBANK | 70 |
| AMAZON | 69 |
| SUPER MICRO COMPUTER | 67 |
| BROADCOM | 66 |
| PLUG POWER | 64 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
